Literature DB >> 20472096

Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia.

Sachin Wani1, Sharad C Mathur, Wouter L Curvers, Vikas Singh, Lorenza Alvarez Herrero, Sandy B Hall, Ozlem Ulusarac, Rachel Cherian, Douglas H McGregor, Ajay Bansal, Amit Rastogi, Basem Ahmed, Mandeep Singh, Srinivas Gaddam, Fiebo J Ten Kate, Jacques Bergman, Prateek Sharma.   

Abstract

BACKGROUND & AIMS: Endoscopic mucosal resection (EMR) is an important diagnostic, staging, and therapeutic tool for patients with Barrett's esophagus (BE)-associated neoplasia. We analyzed the histopathologic characteristics of specimens collected during EMR compared with biopsy specimens from patients with BE and assessed interobserver variability in pathologists' assessment of EMR and biopsy specimens.
METHODS: We evaluated EMR (n = 251) and biopsy (n = 269) specimens collected from patients with BE at 2 tertiary referral centers. A detailed histologic analysis was performed for each EMR and biopsy specimen to determine the grade of dysplasia, depth of the specimen, proportion of specimen with dysplasia, and quality of samples. Interobserver agreement for both biopsy and EMR specimens (among 4 experienced pathologists) was calculated by using kappa statistics.
RESULTS: Histologic analysis showed that submucosa was present in the majority of EMRs, compared with biopsy specimens (88% vs 1%, P < .0001). Almost all biopsy specimens (99%) included lamina propria. However, the muscularis mucosa was observed in only 58% of biopsy specimens. For both EMR and biopsy specimens, the highest grade of dysplasia comprised < or =25% of the total area in >50% of the specimens. Interobserver agreement on the diagnosis of dysplasia was significantly greater for EMR specimens than biopsy specimens (low-grade dysplasia, 0.33 vs 0.22, P < .001; high-grade dysplasia, 0.43 vs 0.35, P = .018).
CONCLUSIONS: Submucosa can be examined in most samples collected from EMR; the distribution of neoplasia is focal within biopsy and EMR specimens. There is more interobserver agreement among pathologists in the analysis of EMR samples than biopsy specimens for the diagnosis of dysplasia. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20472096     DOI: 10.1016/j.cgh.2010.04.028

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  25 in total

Review 1.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

2.  Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.

Authors:  Jacobo Ortiz-Fernández-Sordo; Adolfo Parra-Blanco; Alejandro García-Varona; María Rodríguez-Peláez; Erika Madrigal-Hoyos; Irving Waxman; Luis Rodrigo
Journal:  World J Gastrointest Endosc       Date:  2011-09-16

3.  Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Authors:  Prateek Sharma; David A Katzka; Neil Gupta; Jaffer Ajani; Navtej Buttar; Amitabh Chak; Douglas Corley; Hashem El-Serag; Gary W Falk; Rebecca Fitzgerald; John Goldblum; Frank Gress; David H Ilson; John M Inadomi; Ernest J Kuipers; John P Lynch; Frank McKeon; David Metz; Pankaj J Pasricha; Oliver Pech; Richard Peek; Jeffrey H Peters; Alessandro Repici; Stefan Seewald; Nicholas J Shaheen; Rhonda F Souza; Stuart J Spechler; Prashanth Vennalaganti; Kenneth Wang
Journal:  Gastroenterology       Date:  2015-08-19       Impact factor: 22.682

Review 4.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 5.  Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.

Authors:  Sachin Wani; V Raman Muthusamy; Nicholas J Shaheen; Rena Yadlapati; Robert Wilson; Julian A Abrams; Jacques Bergman; Amitabh Chak; Kenneth Chang; Ananya Das; John Dumot; Steven A Edmundowicz; Glenn Eisen; Gary W Falk; M Brian Fennerty; Lauren Gerson; Gregory G Ginsberg; David Grande; Matt Hall; Ben Harnke; John Inadomi; Janusz Jankowski; Charles J Lightdale; Jitin Makker; Robert D Odze; Oliver Pech; Richard E Sampliner; Stuart Spechler; George Triadafilopoulos; Michael B Wallace; Kenneth Wang; Irving Waxman; Srinadh Komanduri
Journal:  Am J Gastroenterol       Date:  2017-06-01       Impact factor: 10.864

6.  Diagnostic and Management Implications of Basic Science Advances in Barrett's Esophagus.

Authors:  Meghan Jankowski; Sachin Wani
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 7.  Quality Indicators in Endoscopic Ablation for Barrett's Esophagus.

Authors:  Samuel Han; Sachin Wani
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

8.  Oesophageal biopsies are insufficient to predict final histology after endoscopic resection in early Barrett's neoplasia.

Authors:  E Werbrouck; G De Hertogh; X Sagaert; G Coremans; H Willekens; I Demedts; R Bisschops
Journal:  United European Gastroenterol J       Date:  2016-01-06       Impact factor: 4.623

Review 9.  Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma.

Authors:  Cadman L Leggett; Emmanuel C Gorospe; Kenneth K Wang
Journal:  Gastroenterol Clin North Am       Date:  2013-03       Impact factor: 3.806

10.  Correlation between endoscopic forceps biopsies and endoscopic mucosal resection with endoscopic ultrasound in patients with Barrett's esophagus with high-grade dysplasia and early cancer.

Authors:  Prashanthi N Thota; Alaa Sada; Madhusudhan R Sanaka; Sunguk Jang; Rocio Lopez; John R Goldblum; Xiuli Liu; John A Dumot; John Vargo; Gregory Zuccarro
Journal:  Surg Endosc       Date:  2016-07-21       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.